J&J scraps depression testing for potential blockbuster drug

Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy

J&J said aticaprant showed insufficient efficacy in a Phase 3 test in major depressive disorder. The disappointing result follows the Phase 3 failure of a Neumora Therapeutics drug that addresses the same central nervous system target. The post Johnson & Johnson Discontinues Pivotal Depression Drug Trial Due to Lack of Efficacy appeared first on MedCity News.

J&J scraps depression testing for potential blockbuster drug

Analysts say the decision is a “big blow” to a once-promising class of brain therapies that include’s J&J’s aticaprant and a drug from Neumora.

J&J drops Phase III MDD programme due to lack of efficacy

J&J's news about aticaprant's Phase III programme comes two months after Neumora’s MDD drug also failed in a Phase III trial.

J&J axes Phase 3 depression program due to ‘insufficient efficacy’ shortly after Neumora’s study fail

Johnson & Johnson scrapped its Phase 3 program for aticaprant, an experimental and new type of major depressive disorder drug, following "insufficient efficacy," the pharma giant disclosed late Thursday evening. ...